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Melatonin as a potential therapy for sepsis: a phase I dose
escalation study and an ex vivo whole blood model under
conditions of sepsis
Abstract: Sepsis is a massive inﬂammatory response mediated by infection,
characterized by oxidative stress, release of cytokines, and mitochondrial
dysfunction. Melatonin accumulates in mitochondria, and both it and its
metabolites have potent antioxidant and anti-inﬂammatory activities and may
be useful in sepsis. We undertook a phase I dose escalation study in healthy
volunteers to assess the tolerability and pharmacokinetics of 20, 30, 50, and
100 mg oral doses of melatonin. In addition, we developed an ex vivo whole
blood model under conditions mimicking sepsis to determine the bioactivity of
melatonin and the major metabolite 6-hydroxymelatonin at relevant
concentrations. For the phase I trial, oral melatonin was given to ﬁve subjects
in each dose cohort (n = 20). Blood and urine were collected for measurement
of melatonin and 6-hydroxymelatonin, and symptoms and physiological
measures were assessed. Validated sleep scales were completed. No adverse
eﬀects after oral melatonin, other than mild transient drowsiness with no
eﬀects on sleeping patterns, were seen, and no symptoms were reported.
Melatonin was rapidly cleared at all doses with a median [range] elimination
half-life of 51.7 [29.5–63.2] min across all doses. There was considerable
variability in maximum melatonin levels within each dose cohort, but 6-
hydoxymelatonin sulfate levels were less variable and remained stable for
several hours. For the ex vivo study, blood from 20 volunteers was treated
with lipopolysaccharide and peptidoglycan plus a range of concentrations of
melatonin/6-hydroxymelatonin. Both melatonin and 6-hydroxymelatonin had
beneﬁcial eﬀects on sepsis-induced mitochondrial dysfunction, oxidative stress,
and cytokine responses at concentrations similar to those achieved in vivo.
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Introduction
Around 37,000 people die from sepsis in the UK each year
and as many as 8 million every year worldwide. Although
the Surviving Sepsis Campaign, a performance improve-
ment eﬀort by hospitals across Europe, South America,
and the United States, has improved outcomes, the mor-
tality rate remains at 31% overall and >70% in those
patients who go on to develop sepsis-induced multiple
organ failure [1].
Oxidative stress in patients with sepsis has been consis-
tently described over the last 20 yr [2]. Mitochondrial dys-
function initiated by oxidative stress drives inﬂammation
and is generally accepted as playing a major role in sepsis-
induced organ failure [3]. It has been recognized that exog-
enous antioxidants may be useful in sepsis [2], and more
recently, the potential for antioxidants acting speciﬁcally
in mitochondria has been highlighted [4, 5]. We showed
previously that antioxidants targeted to mitochondria,
including melatonin, reduced organ damage in a rat model
of sepsis [6, 7]. Exogenous melatonin has potent antioxi-
dant activity [8, 9], and it accumulates throughout cells,
particularly in mitochondria [10]. Metabolites of melato-
nin also have antioxidant activity, and products from the
reactions with oxidant species are also antioxidants [9, 11,
12].
In vitro models of sepsis show that melatonin and its
major hydroxylated metabolite, 6-hydroxymelatonin, are
both eﬀective at reducing the levels of key inﬂammatory
cytokines, oxidative stress, and mitochondrial dysfunction
[8, 9]. In rat models of sepsis, melatonin reduces oxidative
damage and organ dysfunction and also decreases mortal-
ity [7, 13–15]. The dose needed for antioxidant action is
thought to be considerably higher than that given for
modulation of the sleep–wake cycle, but the actual dose
required in man is unclear, particularly because the major
bioactive eﬀects of oral melatonin in the context of inﬂam-
mation are likely to be mediated primarily by metabolite
levels.
We undertook a phase I dose escalation study in healthy
volunteers using various doses of melatonin. We also devel-
oped an ex vivo whole blood/leukocyte model under condi-
tions mimicking sepsis to determine the relative bioactivity
of melatonin and its major hydroxylated metabolite,
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6-hydroxymelatonin, at concentrations achieved in vivo
after oral dosing.
Materials and methods
Unless otherwise stated, all chemicals were obtained from
Sigma-Aldrich, Poole, Dorset, UK, and were of the high-
est grade available.
Clinical trial
The trial was registered at ClinicalTrials.gov (NCT01
724424) and ISCTRN (17088991).
After obtaining Clinical Trial Authorisation for a Clini-
cal Trial of an Investigative Medical Product (CTIMP)
from the Medicine and Healthcare Regulatory Authority
(MHRA), plus Research Ethics and NHS Research and
Development approval, healthy male volunteers aged
18–30 were invited to take part by advertising. Exclusion
criteria were smoking, body weight above 100 kg, any reg-
ular medication or chronic health condition, or lack of
consent. After obtaining written informed consent, the
study visit took place in a side room of the Intensive Care
Unit at Aberdeen Royal Inﬁrmary, Aberdeen, UK. All
subjects fasted for 12 hr before the study start at 8:00 hr
and were requested to abstain from alcohol for 24 hr pre-
ceding the study visit. EKG electrodes, a noninvasive
blood pressure cuﬀ, a pulse oximeter, and an intravenous
cannula were sited, and a basal blood sample was taken.
Basal measurements of heart rate, oxygen saturation,
EKG parameters, and blood pressure were recorded.
Subjects then took melatonin (N-acetyl-5-methoxytrypta-
mine or N-[2-(5-methoxy-1H-indol-3-yl)ethylacetamide) as
10 mg capsules (prepared by Nu-Pharm Laboratories
Ltd., Deeside, Cheshire, UK, using melatonin manufac-
tured and supplied by Flamma s.p.a., Bergamo, Italy).
A standard open-label dose escalation study design was
used with sequential assignment of cohorts of ﬁve subjects
each to doses of 20, 30, 50, and 100 mg. Venous blood
samples were taken after 10, 30, 60, and 120 min and 3, 4,
and 6 hr for melatonin and 6-hydroxymelatonin measure-
ment, respectively. Routine biochemistry/hematology
analyses were conducted at baseline and 6 hr, and a fur-
ther blood sample for melatonin and 6-hydroxymelatonin
was taken at 24 hr. Urine was also collected for 6 hr. Sub-
jects ate a standardized sandwich lunch exactly 3 hr after
the melatonin capsules, and water was allowed ad libitum.
Subjects were questioned at 30-min intervals about any
symptoms and whether they felt drowsy.
Subjects completed validated sleep scales about their
sleep the day before the study visit, the study visit day
itself, and 1 wk later. The Verran and Snyder-Halpern
sleep scale uses 100-mm visual analogue scales to record
three domains: sleep disturbance, sleep eﬃciency, and
sleep supplementation [16].
A safety algorithm was designed which prospectively
deﬁned gradings for each biochemical and physiological
parameter with clear stopping criteria. After each dose
cohort, an independent Data Monitoring Committee
(DMC) comprising a biochemist and two intensive care
consultants, one local and one external, assessed the data
and decided whether the investigators should continue to
the next dose cohort.
Measurement of melatonin and 6-hydroxymelatonin
Blood samples were stored at 4°C until clotted and then
immediately centrifuged, and the serum was frozen at
80°C until assay. Melatonin was measured using a
Thermo Surveyor-TSQ Quantum liquid chromatography-
tandem mass spectrometry (LC-MS/MS) system (Thermo
Scientiﬁc, Hemel Hempstead, UK), which was set up and
validated in-house. Sample aliquots (100 lL) were spiked
with 10 lL of 60 ng/mL N-acetyltryptamine (internal
standard), and plasma proteins were precipitated by the
addition of 100 lL of 1.5% (w/v) sulfosalicylic acid. After
vortex mixing, 500 lL of water was added and the sam-
ples were centrifuged at 4000 g for 10 min at 4°C. A 5-lL
aliquot of the supernatant was injected onto the LC-MS/
MS system equipped with a 150 9 2.1 mm, ACE 3 l C18
column (Hichrom Ltd, Reading, UK) maintained at 50°C.
Samples were maintained at 4°C prior to injection. Elution
was achieved under isocratic conditions with a mobile
phase of water/methanol (50/50) containing 0.1% (v/v)
formic acid at a ﬂow rate of 200 lL/min. Electrospray ion-
ization was operated in positive ion mode with conditions
optimized by ﬂow injection analysis of the individual com-
pounds: spray voltage, 4000 V; sheath gas pressure, 10
(arbitrary units); auxiliary gas pressure, 5 (arbitrary units);
capillary temperature, 375°C; skimmer oﬀset, 10V; colli-
sion pressure, 1.6 mTorr; and collision energy, 13 V. Tan-
dem mass spectrometry was performed in single reaction
monitoring (SRM) mode using the transition m/z 233–m/z
174 for melatonin and m/z 203–m/z 144 for N-acetyltryp-
tamine. Under these conditions, melatonin eluted at
3.1 min and N-acetyltryptamine eluted at 3.5 min. Quanti-
tation was based on an internal standard method using
multilevel calibration curves (0.5–100 ng/mL melatonin)
prepared in 5% bovine serum albumin with concentration
plotted against the peak area ratio of the analyte to the
internal standard. Weighted least squares regression analy-
sis was carried out using Thermo Xcalibur software v.2.07
SP1 (Thermo Scientiﬁc, Hemel Hempstead, UK).
The metabolite 6-hydroxymelatonin was measured in
serum and urine as the sulfated form using commercially
available enzyme immunoassays (Cusabio Biotech, Hubei
Province, China, and US Biologicals, Salem, MA, USA,
respectively).
Ex vivo study
After obtaining University of Aberdeen College of Life
Sciences and Medicine Ethics Review Board approval, a
second group of 20 healthy male volunteers was invited to
take part by advertising. Exclusion criteria were again
smoking, body weight above 100 kg, any regular medica-
tion or chronic health condition, or lack of consent.
A single venous blood sample was collected at 9:00 hr
into lithium-heparin tube and used immediately for whole
blood experiments or allowed to cool to room temperature
before isolating leukocytes. A sample of blood was also
collected into an EDTA tube for hemoglobin and full cell
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count determination. Leukocytes were isolated by sedi-
menting blood through 4% succinylated gelatine (‘Gelofu-
sine’, B. Braun Medical Ltd., Sheﬃeld, UK). Brieﬂy,
whole blood was centrifuged at 750 g for 10 min and the
plasma removed and replaced by equal volumes of Gelofu-
sine and RPMI 1640 medium (GE Healthcare, Chalfront
St Giles, UK) supplemented with 10% fetal calf serum.
The tube was then placed at 37°C for 30 min at a slight
angle to allow erythrocytes to sediment. The leukocyte-
rich upper layer was then aspirated and centrifuged at
500 g for 10 min, and the remaining erythrocytes were
removed by hypotonic shock. The leukocyte pellet was
then washed and resuspended in medium.
For experimentation, whole blood or isolated leukocytes
were placed into 24- or 96-well plates (see experimental
detail below) in the presence of 2 lg/mL lipopolysaccha-
ride (LPS, from E. coli strain 055:B5) plus 20 lg/mL pep-
tidoglycan (PepG, from S. aureus strain 6571), prepared
as described previously [17]. In addition, blood or cells
were also exposed to solvent control or either melatonin
or 6-hydroxymelatonin (Sigma-Aldrich Ltd) dissolved in
ethanol (<1% v/v) at 0, 0.01, 0.1, 1, 10, 100, or 1000
ng/mL for 18 hr at 37°C in a humidiﬁed atmosphere of
95% air/5% CO2. The amount of LPS and PepG used in
this study was determined based on optimal release of
interleukin (IL)-6 in preliminary experiments (data not
shown).
Cytokine and lipid hydroperoxide levels
Whole blood was treated as above in 24-well plates. Levels
of IL-6 and IL-10 were measured in plasma using
commercially available enzyme immunoassay kits (R&D
Systems Europe Ltd, Oxford, UK). Plasma lipid hydroper-
oxide (LPO) levels were measured using a commercially
available spectrophotometric kit (Cambridge Bioscience
Ltd, Cambs, UK) after extracting LPO into chloroform.
Precision data in our hands were as follows: intra-assay—
IL-6 = 1.4%, IL-10 = 1.9%, LPO = 1.7%; interassay—
IL-6 = 6.3%, IL-10 = 6.2%; LPO = 2.0%.
Respiratory burst
Whole blood (200 lL) was added to 800 ll phosphate-
buﬀered saline (PBS, 1.37 M NaCl, 27 mM KCl, 95 mM
NaH2PO4, 15 mM KH2PO4, pH 7.4) containing 5 mM glu-
cose and treated immediately as described previously.
Samples (100 lL) were transferred to 96 wells, and basal
luminescence was measured before the addition of sodium
luminol using an automated system (1.25 mM ﬁnal concen-
tration). Luminescence was measured every minute until a
plateau was reached. Results were normalized to total
monocyte/neutrophil number and hemoglobin content.
Mitochondrial superoxide production
Mitochondrial superoxide production was determined in
intact leukocytes in 96-well plates following cell treatments
as described previously [18]. Brieﬂy, cells were washed
twice with PBS before being loaded with 5 lM MitoSoxTM
(Life Technologies, Paisley, UK) for 10 min at 37°C and
then washed immediately with warm PBS containing
5 mM glucose. Fluorescence was measured without delay
at an excitation wavelength of 485 nm and emission wave-
length of 590 nm.
Intracellular total radical production
Total radical production was measured in intact leuko-
cytes in 96-well plates following cell treatment as above.
Brieﬂy, leukocytes were washed with PBS before being
loaded with 50 lM oxidation-sensitive 5-(6)-carboxy-2,70-
dichlorodihydroﬂuorescein diacetate (CDHFD) or 50 lM
oxidation-insensitive 5,(6)-carboxy-2,7-dichloroﬂuorescein
(CDF) for 60 min in the dark at 37°C. Cells were then
washed twice with PBS, and the rate of total radical for-
mation was determined by subtracting CDF ﬂuorescence
from CDHFD ﬂuorescence by continuous recording until
saturation was reached, at excitation/emission wavelengths
of 485/530 nm [19].
Mitochondrial membrane potential
Mitochondrial membrane potential was analyzed in iso-
lated leukocytes in 96-well plates using the ﬂuorescent
probe 5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazol-
carbo-cyanine iodide (JC-1). Brieﬂy, following cell treat-
ments, leukocytes were washed twice with PBS and then
incubated for 30 min with 10 lg/ml JC-1 in PBS contain-
ing 5 mM glucose at 37°C in the dark. Following incuba-
tion, cells were washed twice with PBS, and the red and
green ﬂuorescence was measured immediately (excitation,
490 nm; emission, 590 or 520 nm). In intact mitochondria,
‘J aggregates’ form and JC-1 ﬂuoresces red. When the
mitochondrial membrane potential decreases, the JC-1
assumes a monomeric form and ﬂuoresces green; results
are expressed as the ratio of red to green ﬂuorescence [20].
Oxygen consumption
Leukocyte oxygen consumption was measured after cell
treatments using a Clark-type oxygen electrode. Brieﬂy,
1 9 106 cells were transferred to a 1-mL oxygen electrode
chamber maintained at 37°C containing RPMI medium
supplemented with 10% v/v FCS. Oxygen consumption
was measured continuously for 15 min [21].
Phagocytosis
Neutrophils were isolated from whole blood using Poly-
morphprepTM (Axis-Shield, Oslo, Norway), diluted in
RPMI 1640 containing 10% autologous serum, and used
within 1 hr of isolation (viability >97%). E. coli stain 8959
(Public Health England, Porton Down, UK) were grown
overnight in nutrient broth at 37°C with rotation at
250 rpm. Freshly prepared 2 9 106 neutrophils were
added to 2 9 107 cfu E. coli plus 1 or 100 pg/mL melato-
nin or 6-hydroxymelatonin or solvent control. Identical
control tubes were prepared without neutrophils to deter-
mine the starting number of bacteria and growth over the
time course of the experiment. Tubes were rotated end-
over-end at 37°C for 30, 60, and 90 min, and samples were
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removed into ice-cold PBS and centrifuged at 4°C to pellet
the neutrophils. The supernatant containing extracellular
bacteria was removed, and the neutrophil pellet was resus-
pended in water at pH 11.0 and incubated at room tem-
perature for 5 min and then vortexed thoroughly for 5 s
to release intracellular bacteria. Each sample was diluted
and spread on an agar plate and incubated overnight at
37°C, and colonies were then counted.
Statistics
Phase I dose escalation trial
Multilevel linear modeling was used to analyze oxygen sat-
uration, blood pressure, heart rate, and ECG measures.
Generalized linear models were used to analyze variables
with two measures at baseline and 6 hr. The models all
evaluated the eﬀect of increasing melatonin doses on each
outcome variable and were adjusted for age, weight, and
height. Assumptions were checked, and where necessary,
transformed data were used. The analyses were carried out
using SPSS version 21 (IBM, Portsmouth, UK) or SAS
version 9.3 (SAS Institute Inc., Cary, NC, USA) using
two-tailed tests with P < 0.05 used to indicate statistical
signiﬁcance. The visual analogue scores for the sleep scales
were measured independently by two observers and
entered into an Excel spreadsheet for summation of the
total domain score. Data were analyzed nonparametrical-
ly. Each domain total from the three sleep scales was com-
pared using the Friedman test for repeated measures, with
Wilcoxon signed-rank post hoc test if P < 0.05. Domain
totals between each dose cohort were compared using
Kruskal–Wallis followed by Mann–Whitney U post hoc
test if appropriate. Multiple comparisons were adjusted
using Bonferroni correction where appropriate.
Ex vivo study
Data were not normally distributed and so are presented
as median and interquartile range. Data were analyzed
using Mann–Whitney U-test or Friedman’s test, with
either post hoc testing using Dunn’s test for multiple com-
parisons or Page’s L trend test as appropriate.
Results
Thirty-one subjects volunteered, but eight fulﬁlled the
exclusion criteria and so were not recruited: Of these, ﬁve
were taking regular medication or had chronic health con-
ditions, two were occasional smokers, and one had a body
weight >100 kg. Another three subjects consented but sub-
sequently decided they could not spare the time. Twenty
subjects aged 21–27 years completed the study visit and
the 1-wk follow-up.
There was little diﬀerence in baseline characteristics
between dose cohorts (Table 1). There were no grounds
for noncontinuation, and the DMC recommended pro-
gression after each dose cohort. There were no serious
adverse events and no adverse events attributable to the
study drug. No subject reported nausea, headache, vomit-
ing, diarrhea, or abdominal pain at any time during the
study visit or the 1-wk follow-up period. There were statis-
tically signiﬁcant decreases in some biochemical parame-
ters between baseline and 6 hr, but none were of clinical
signiﬁcance and there were no eﬀects of melatonin dose
(Table 2). Analysis of physiological measurements over
time revealed some statistically signiﬁcant changes related
to time (oxygen saturation, diastolic blood pressure) or
dose (systolic blood pressure), but none of these changes
were considered to be clinically signiﬁcant or of any con-
cern (Fig. 1).
Fifteen of the 20 subjects reported drowsiness at some
point during the study visit. There were 17 separate time
points at which subjects in the 20 mg dose cohort reported
feeling sleepy, six in the 30 mg cohort, ﬁve in the 50 mg
cohort, and 17 incidences in the 100 mg cohort; thus, there
were as many reports of drowsiness for the 20 mg dose
cohort as the 100 mg cohort and no obvious relationship
to dose. All subjects were fully recovered by 6 hr and were
able to go home alone.
Sleep disturbance is measured as mid-sleep awakening,
wake after sleep onset, movement during sleep, soundness
of sleep, and quality of disturbance, while latency charac-
teristics include sleep latency and quality of latency. The
maximum available total score for the sleep disturbance
domain is 700, and a lower score indicates less sleep dis-
turbance. The median [range] domain totals are given in
Table 3. It can be seen that sleep disturbance was variable
—but minimal—in most subjects and unrelated to the dose
of melatonin. There was no diﬀerence in the time taken to
fall asleep (sleep latency) or the sleep disturbance domain
total between the three points at which sleep scales were
completed.
Sleep eﬃciency is both the perceived quality and the
duration of sleep. The maximum total score possible is
500 with a higher score representing greater sleep eﬃ-
ciency. Sleep eﬃciency was consistent and was similar in
all subjects at all times, independent of melatonin dose
(Table 3). There was no change in perceived sleep quality
or the sleep eﬃciency domain total between any of the
completed sleep scales in any of the dose cohorts.
The sleep supplementation domain measures how much
extra sleep time subjects had during the day. The maxi-
mum total score possible is 400, and the higher the total
score was, the more supplemental sleep was needed. We
found that supplementary sleep duration was variable
between individuals but again was unrelated to melatonin
dose (Table 3). There was no diﬀerence in the total sleep
periods between the sleep scales.
The technique for measuring melatonin was very sensi-
tive with a lower limit of quantitation of 0.5 ng/mL. The
Table 1. Age, weight, and height data by dose cohort
Dose
mg
Age
years
Weight
kg Height cm
20 25 [23–26] 75 [73–94] 179 [173–203]
30 22 [21–22] 73 [57–99] 183 [170–191]
50 21 [21–27] 76 [73–86] 180 [178–191]
100 22 [21–22] 80 [73–85] 188 [179–193]
Median [range], n = 5 per dose cohort.
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mean intra-assay precision (percentage relative standard
deviation, n = 6) was 4.7% at 1 ng/mL and 2.6% at
80 ng/mL. Interassay precision was 4.1% at 1 ng/mL and
1.0% at 80 ng/mL, and recovery of melatonin added to
serum was 96% at 0.5 ng/mL and 105% at 100 ng/mL.
For 6-hydroxymelatonin sulfate determination in serum,
the mean intra-assay precision was 3.0% and the inter-
assay precision was 5.0%. The precision of the urine
6-hydroxymelatonin sulfate assay was 4.1% intra-assay
and 15.8% inter-assay.
In all subjects, melatonin was detectable in serum at
10 min after taking the oral dose and was rapidly cleared,
with maximum levels reached at 30–60 min (Table 4).
Melatonin concentration was variable between individuals
even after the same melatonin dose, but there was a signiﬁ-
cant eﬀect of melatonin dose on both the area under the
concentration curve (AUC, P = 0.0065) and maximum
concentration (Cmax, P = 0.0018). Levels of 6-hydroxyme-
latonin sulfate were also detectable in serum by 10 min
with maximum levels reached at a median of 120 min, but
were less variable than melatonin, and remained broadly
stable between 1 and 6 hr but were back at baseline levels
at 24 hr (Fig. 2). Fig. 3 shows the relationship between
melatonin and 6-hydoxymelatonin sulfate concentrations
in individual subjects in the 50 mg dose cohort.
Urinary excretion of 6-hydroxymelatonin sulfate in the
6 hr after melatonin administration is shown in Table 5.
There was a signiﬁcant dose eﬀect (P = 0.0018) although
there was considerable inter-individual variation.
In the ex vivo study, IL-6 and IL-10 were both signiﬁ-
cantly increased in plasma from blood exposed to LPS/
PepG (both P < 0.0001, Fig. 4) compared with solvent
control. Exposure of blood to LPS/PepG plus melatonin
or 6-hydroxymelatonin caused a signiﬁcant dose-dependent
Table 2. Biochemistry/hematology data by dose cohort
Measure
Melatonin dose (mg)
20 30 50 100
Hemoglobin g/L
Baseline 147 [139–161] 138 [127–142] 149 [142–169] 147 [145–148]
6 hr 145 [136–153] 133 [128–148] 145 [145–166] 141 [139–147]
Leukocytesa 109/L
Baseline 5.0 [3.7–6.9] 5.6 [4.3–8.7] 4.9 [4.2–5.7] 5.3 [5.3–6.7]
6 hr 5.0 [4.2–6.7] 5.3 [4.2–6.6] 5.7 [4.3–6.7] 5.6 [4.2–6.4]
AST Units/L
Baseline 33 [24–34] 25 [18–30] 24 [20–51] 23 [17–41]
6 hr 24 [17–25] 21 [16–29] 22 [17–33] 23 [16–36]
Bilirubin lmol/L
Baseline 17 [14–29] 16 [9–38] 18 [7–23] 11 [9–14]
6 hr 15 [12–29] 17 [8–35] 19 [9–23] 14 [9–17]
Creatinine lmol/L
Baseline 83 [74–86] 73 [70–96] 71 [68–77] 80 [62–85]
6 hr 73 [71–83] 68 [60–92] 66 [63–73] 79 [56–84]
Glucoseb mmol/L
Baseline 5.0 [4.3–5.3] 4.5 [3.7–5.6] 4.1 [3.6–4.7] 4.4 [3.9–5.0]
6 hr 4.4 [3.8–5.1] 4.4 [4.4–5.4] 4.0 [3.7–5.3] 4.2 [3.9–5.8]
Potassiumc mmol/L
Baseline 4.0 [3.9–4.6] 3.9 [3.5–4.2] 3.7 [3.6–3.8] 4.0 [3.6–4.0]
6 hr 3.8 [3.7–3.9] 3.9 [3.4–4.3] 3.8 [3.7–3.9] 3.8 [3.7–4.0]
Sodiumd mmol/L
Baseline 140 [140–141] 140 [138–140] 142 [140–143] 141 [140–143]
6 hr 141 [139–142] 140 [139–142] 141 [139–142] 141 [140–141]
Median [range], n = 5 per dose cohort.
aBaseline >6 hr (P < 0.001) across all subjects, no eﬀect of dose.
bBaseline >6 hr (P = 0.013) across all subjects, no eﬀect of dose.
cBaseline >6 hr (P < 0.001) across all subjects, no eﬀect of dose.
dBaseline >6 hr (P = 0.001) across all subjects, no eﬀect of dose.
Fig. 1. Physiological measures in healthy subjects over 6 hr after
receiving an oral dose of melatonin. (A) Heart rate, (B) oxygen
saturation, (C) systolic blood pressure, and (D) diastolic blood
pressure. Median values shown for clarity, n = 5 subjects per dose
cohort. Multilevel linear modeling showed that oxygen saturation
and diastolic blood pressure decreased over time, unrelated to
dose (P = 0.017 and P < 0.001, respectively), and systolic blood
pressure increased with melatonin dose (P < 0.005).
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decrease in IL-6 (Fig. 4A), but IL-10 was unaﬀected by
either drug (Fig. 4B). Likewise, LPO was signiﬁcantly
higher in blood exposed to LPS/PepG, and both melato-
nin and 6-hydroxymelatonin caused a signiﬁcant dose-
dependent decrease (Fig. 4C). The respiratory burst also
increased upon exposure to LPS/PepG, and this was sig-
niﬁcantly decreased when blood was co-treated with LPS/
PepG plus melatonin or 6-hydroxymelatonin (Fig. 5).
Exposure of isolated leukocytes to LPS/PepG resulted
in a signiﬁcant increase in mitochondrial membrane poten-
tial, total radical production, oxygen consumption, and
mitochondrial superoxide production (Table 6). Co-expo-
sure of cells to LPS/PepG plus melatonin or 6-hydroxyme-
latonin resulted in decreased membrane potential, radical
production, and oxygen consumption (Table 6). When
isolated neutrophils were cultured with E. coli, all bacteria
were phagocytosed after 30 min regardless of treatment
and there was no diﬀerence in the number of viable intra-
cellular bacteria, showing that neither melatonin nor 6-
hydroxymelatonin reduced neutrophil phagocytosis or kill-
ing of engulfed bacteria (data not shown).
Discussion
We found that large oral doses of melatonin in healthy
volunteers were very well tolerated with no safety concerns
and no clinically relevant changes in any physiological or
Table 3. Sleep scale domain total scores by dose cohort
Dose Timing of sleep scale Disturbance domain Eﬃciency domain Supplementation domain
20 mg Before study visit 59 [16–423] 397 [310–461] 2 [2–109]
Study visit 46 [8–145] 443 [324–490] 22 [0–94]
Week after 99 [5–200] 429 [400–468] 2 [0–11]
30 mg Before study visit 72 [36–180] 376 [313–420] 16 [7–79]
Study visit 37 [29–142] 409 [272–487] 59 [4–139]
Week after 81 [25–263] 313 [272–412] 36 [21–87]
50 mg Before study visit 59 [11–104] 436 [268–456] 7 [0–160]
Study visit 77 [13–234] 413 [312–458] 13 [2–35]
Week after 60 [13–168] 399 [369–430] 1 [0–135]
100 mg Before study visit 65 [61–464] 329 [317–453] 9 [0–154]
Study visit 21 [10–205] 449 [251–458] 82 [49–137]
Week after 95 [71–190] 379 [319–469] 18 [13–108]
Median [range], n = 5 per dose cohort.
No signiﬁcant changes between time points or dose cohorts.
Table 4. Melatonin pharmacokinetic data in individual subjects
Dose and subject
ID no.
AUCa
ng/ml/min
Half-life
mins
Cmaxb
ng/ml
Tmax
min
20 mg
1 1102 62.01 12.80 30.00
2 3266 52.62 35.70 60.00
3 3405 58.76 30.33 60.00
4 1564 50.38 20.86 30.00
5 13616 52.07 147.68 30.00
30 mg
6 2491 48.33 30.09 30.00
7 1866 48.14 33.67 30.00
8 1304 71.62 12.95 30.00
9 822 63.22 6.25 60.00
10 1640 62.96 8.51 120.00
50 mg
11 6034 55.58 75.42 30.00
12 1812 45.06 24.53 30.00
13 8915 51.39 113.78 30.00
14 4234 41.75 67.84 30.00
15 6554 53.09 91.38 30.00
100 mg
16 9570 44.41 103.22 60.00
17 5639 29.47 94.00 60.00
18 18229 47.32 220.26 30.00
19 4458 45.18 47.71 60.00
20 11062 55.89 138.83 30.00
AUC, area under the concentration curve.
aSigniﬁcant eﬀect of dose (P = 0.006).
bSigniﬁcant eﬀect of dose (P = 0.006).
Table 5. Urine 6-hydroxymelatonin in individual subjects
Dose and
subject
ID no.
Total
6-hydroxymelatonin
excreted in 6 hra mg
Median dose
cohort total
6-hydroxymelatonin
excreted in 6 hr mg
20 mg
1 2.22 3.72
2 4.38
3 3.72
4 6.20
5 2.96
30 mg
6 3.81 5.08
7 4.60
8 8.80
9 5.55
10 5.08
50 mg
11 34.98 13.95
12 28.45
13 13.95
14 11.23
15 5.82
100 mg
16 22.92 37.09
17 37.09
18 47.09
19 34.54
20 66.03
aSigniﬁcant eﬀect of dose (P = 0.0018).
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biochemical measures. The concentrations of melatonin in
the blood were variable and were rapidly cleared, but lev-
els of the metabolite 6-hydroxymelatonin sulfate were
more consistent and remained stable for several hours,
returning to baseline levels by 24 hr. The levels of both
melatonin and 6-hydroxymelatonin achieved after oral
dosing were shown to be bioactive in terms of antioxidant/
anti-inﬂammatory eﬀects in an ex vivo model of sepsis.
Sepsis can be deﬁned as an uncontrolled immune and
inﬂammatory response to an infectious insult, resulting in
oxidative stress, massive cytokine release, and mitochon-
drial dysfunction. The role of damage to mitochondria in
the pathophysiology of sepsis and subsequent organ dys-
function is widely accepted [3–5]. Melatonin is known to
have a plethora of antioxidant and anti-inﬂammatory
eﬀects likely to be of beneﬁt in sepsis [4, 5, 7–9].
Oral bioavailability of melatonin is low and has been
estimated to be approximately 15% of the parent
compound [22–24] with rapid clearance. The low bioavail-
ability of melatonin and the marked interindividual vari-
ability that are reported here have been reported
previously [24, 25] and are a consequence of variable ﬁrst-
pass extraction in the liver, due to genetic diﬀerences in
the activity of cytochrome P450 enzymes, notably
CYP1A1 but also CYP1A2, which convert melatonin to
the 6-hydroxymelatonin metabolite before it enters the sys-
temic circulation [26–28]. The majority of melatonin is
converted to 6-hydroxymelatonin in the liver, then sulfated
(~80%) or glucuronidated (~10%), and excreted in urine.
The remainder can be demethylated back to N-actylseroto-
nin [29]. In addition, 6-hydroxylmelatonin sulfate can be
formed at extrahepatic sites by CYP1B1 [27]. In addition
to enzymatic processes, 6-hydroxymelatonin can also be
generated by nonenzymatic means via reaction with peroxy-
nitrite or hydroxyl radical such that during oxidative
stress, persistent production of 6-hydroxymelatonin might
be expected.
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Fig. 2. Seum 6-hydroxymelatonin sulfate levels in healthy subjects
over 6 hr after an oral dose of melatonin. Median and full range
shown, n = 5 per dose cohort. There was a signiﬁcant eﬀect of
dose (P = 0.028), and levels after 30, 50, or 100 mg were signiﬁ-
cantly higher than after 20 mg (all P < 0.001).
10 30 60 120 180 240 360
0
20
40
60
80
100
120
140
160
Time aer 50 mg oral dose (min)
M
el
at
on
in
 n
g/
m
L
6-hydroxy m
elatonin ng/m
L 
10
20
30
40
50
60
70
80
90
0
Fig. 3. Serum melatonin (red) and serum 6-hydroxymelatonin
(blue) in individual subjects following an oral dose of 50 mg mela-
tonin (n = 5 per dose cohort). Lines show median values.
Table 6. Mitochondrial function in isolated leukocytes
Melatonin or
6-hydroxymelatonin
ng/ml
Mitochondrial
membrane potential
Red/green
ﬂuorescence ratio
Oxygen consumption
nMoles O2/min/mg
protein
Total radical
production
DFluorescence
x 103/min/106 cells
Mitochondrial superoxide
production
Fluorescence units 9103
Solvent control 23.9 [18.3–27.0] 17.9 [14.2–27.2] 56 [34–61] 260 [250–270]
Melatonin +
LPS/PepG
P < 0.0001 P < 0.0001 P < 0.0001 P = 0.0029
0 28.6 [21.1–33.3] # 36.1 [23.0–56.2] # 88 [51–127] # 290 [270–310] #
0.01 21.6 [15.9–24.3]* 27.4 [18.6–38.6]* 59 [39–97]* 280 [270–300]*
0.1 19.9 [15.8–24.3]* 22.6 [16.3–32.4]* 62 [38–80]* 270 [250–300]*
1 21.0 [14.5–25.8]* 24.3 [18.2–41.5]* 62 [37–97]* 270 [260–300]*
10 19.6 [15.6–28.3]* 25.6 [20.5–36.8]* 60 [37–91]* 270 [250–300]*
100 23.2 [15.4–26.7]* 32.4 [25.7–43.4] 59 [35–111]* 270 [250–290]*
1000 24.5 [15.2–28.6]* 37.7 [28.1–48.4] 66 [43–105]* 270 [270–280]*
Solvent control 21.5 [16.1–23.3] 19.0 [14.9–30.9] 57 [41–70] 250 [230–280]
6-Hydroxymelatonin
+ LPS/PepG
P < 0.0001 P = 0.0037 P < 0.0001 P = 0.0035
0 29.2 [21.8–32.8] # 33.1 [21.1–53.4] # 89 [60–122] # 290 [260–300] #
0.01 21.1 [16.1–23.3]* 19.8 [13.8–26.7]* 76 [45–117]* 270 [250–300]*
0.1 20.4 [17.2–23.9]* 20.0 [12.9–25.2]* 61 [46–108]* 280 [270–300]*
1 21.5 [19.1–26.7]* 18.9 [15.1–25.2]* 68 [40–93]* 280 [260–300]*
10 18.9 [15.8–24.4]* 21.5 [14.8–25.9]* 64 [50–110]* 270 [250–300]*
100 22.2 [18.9–25.0]* 21.3 [15.3–26.7]* 70 [54–109]* 270 [260–300]*
1000 24.6 [16.6–27.8]* 19.4 [16.4–22.6]* 61 [47–72]* 270 [260–290]*
6-OH Melatonin = 6-hydroxymelatonin. Median [interquartile range], n = 20. P-value shown is Friedman’s test across LPS/PepG groups.
#Signiﬁcantly diﬀerent from solvent control (Wilcoxon signed ranks) and *signiﬁcantly diﬀerent from LPS/PepG alone (Dunn’s test)
P < 0.05.
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We and others have reported a protective eﬀect of mela-
tonin in animal models of sepsis [7, 13–15, 30], suggesting
a potential beneﬁcial eﬀect of melatonin in patients with
sepsis. It is now apparent that 6-hydroxymelatonin has
similar antioxidant eﬀects to melatonin and protects
against various oxidative stress initiators [11, 29, 31–34]
such that after oral dosing with melatonin, antioxidant
eﬀects may be mediated by 6-hydroxymelatonin. We
undertook this dose escalation study to determine the tol-
erance of large oral doses of melatonin and the levels of
melatonin and 6-hydroxymelatonin sulfate achieved and
related this to a physiologically relevant ex vivo model of
sepsis. Melatonin metabolism has been commonly moni-
tored using measurement of urine excretion of 6-hydrox-
ymelatonin sulfate, with maximum levels up to 2 mg/hr
reported to occur between 04:00 and 08:00 but negligible
amounts at other times [35]; however, there are few reports
of 6-hydroxymelatonin in the serum after oral doses of
melatonin in humans. Data from a single subject after an
oral dose of 1 mg melatonin showed that plasma 6-hydro-
ymelatonin sulfate levels were elevated for 6 hr after mela-
tonin administration, measured using radioimmunoassay,
concurring with our ﬁndings [36]. In another study by
H€artter and colleagues [37], a maximum plasma level of
total 6-hydroxymelatonin from a single subject after tak-
ing 25 mg oral melatonin was reported to be approxi-
mately 600 ng/mL, again persisting for over 6 hr. H€artter
et al. undertook enzymatic conversion of both the sulfate
and glucuronidate forms of 6-hydroxymelatonin before
liquid chromatography–mass spectrometry, to give the
total conjugated 6-hydroxymelatonin level, but this tech-
nique incurred large losses during the hydrolysis step [37].
We found that 6-hydroxymelatonin was extremely unsta-
ble—hence our decision to measure 6-hydroxymelatonin in
serum as the sulfated form using a validated enzyme
immunoassay rather than using liquid chromatography.
The long-term stability of 6-hydroxymelatonin sulfate has
been previously reported [38].
In some countries such as the USA, melatonin is consid-
ered a food supplement, whereas in Europe, it is consid-
ered a neurohormone. The only licensed melatonin
product in the UK is a slow-release melatonin agonist
licensed for use in sleep disorders. In the present study,
under EU legislation, melatonin was considered an investi-
gational medicinal product and capsules were manu-
factured from chemically synthesized melatonin.
Administration of melatonin in both preclinical and
human studies, even at supraphysiological doses, has an
excellent safety proﬁle, although there is little in the way
of robust toxicological investigation allowing an evalua-
tion of risk in clinical trials [39]. We found that there was
no evidence of side eﬀects after single doses of up to
100 mg oral melatonin in healthy young men. Minor
decreases in leukocyte count, glucose, potassium, and
sodium were probably related to the dilutional eﬀects of
drinking water in subjects who had been fasting. There
were also minor changes in oxygen saturation and blood
pressure over time, but again, no values were of clinical
signiﬁcance or concern at any time point. Small decreases
in systolic blood pressure and heart rate have been
reported after a single dose of 5 mg melatonin at 14:00 or
21:00 hr in healthy subjects, but values remained well
within normal ranges [40, 41]. There have been previous
anecdotal reports of nausea, headache, and itching in
Fig. 4. (A) Plasma interleukin-6 (IL-6), (B) IL-10, and (C) lipid
hydroperoxide (LPO) from whole blood treated with solvent con-
trol (green), lipopolysaccharide and peptidoglycan G (LPS/PepG)
plus melatonin (red) or 6-hydroxymelatonin (blue). Median and
interquartile range, n = 20 subjects. P-value is Page’s trend test.
and * = signiﬁcantly lower than with LPS/PepG alone (Wilcoxon
Signed Ranks, P < 0.0001)
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Fig. 5. Respiratory burst in whole blood treated with solvent con-
trol (green), lipopolysaccharide and peptidoglycan G (LPS/PepG)
plus melatonin (red) or 6-hydroxymelatonin (blue). Median and
interquartile range, n = 20 subjects. P-value is Page’s trend test.
and * = signiﬁcantly lower than with LPS/PepG alone (Wilcoxon
Signed Ranks, P < 0.0001)
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healthy subjects and various patient groups [42, 43]. How-
ever, there are few previous comprehensive reports of
rigorous and comprehensive monitoring of physiological
and biochemical parameters in diﬀerent melatonin dose
cohorts. Using a nonsuggestive approach, we had no
reports of any symptoms at any dose, either immediately
after dosing or up to 1 wk afterward. No eﬀect of chronic
administration of melatonin on a multitude of biochemical
measures was also seen in previous randomized, double-
blinded study of subjects taking 10 mg daily for a month
[43], and there was also no diﬀerence in the incidence of
adverse events such as nausea and headache between those
taking melatonin and those given placebo [43].
Melatonin has been reported to cause drowsiness [44,
45] and indeed has been used at doses of 1–5 mg to treat
sleep disorders and jet lag [46]. In our study, most subjects
did report subjective drowsiness, and some, but not all, fell
asleep, but the number of subjects who were drowsy or fell
asleep appeared unrelated to the melatonin dose. All our
subjects were lying supine on a bed in a warm and sopo-
riﬁc environment; we therefore thought it likely that sub-
jective drowsiness levels would be overestimated, and so
we were somewhat surprised that more subjects did not
report feeling drowsy after even the highest dose of mela-
tonin. All subjects were alert and able to go home at the
end of the study visit (6 hr after the melatonin dose). Mel-
atonin also did not change the objective assessment of sub-
sequent sleeping patterns in any subject. Although several
subjects reported subjectively that they ‘slept very well’ the
night of the study visit, this was not reﬂected in the
recorded quality or duration of sleep in the completed
sleep scales. The sleep scale used is a validated scale used
extensively for assessing sleep eﬃcacy and disturbance and
the need for supplementary daytime sleep [16]. However,
the day of the week on which the sleep scales were com-
pleted may of course have had an impact on the data, and
any alcohol intake the day after the study visit or a week
later may also have aﬀected results.
It was reported previously that 9 mg oral melatonin at
09:30 reduced sleep latency (i.e., time to fall asleep),
assessed using a multiple sleep latency test at 2-hr inter-
vals, with subjects forced to stay awake in-between [47].
Another double-blind trial of up to 40 mg melatonin given
at 10:00 showed decreased sleep latency, increased sleep
duration, and decreased wake after sleep onset 2 hr after
all doses of melatonin, measured polygraphically [44].
However, in a randomized double-blind study of 30 sub-
jects given 10 mg melatonin daily at night for 28 day,
polysomnographic recording revealed no eﬀect of melato-
nin on sleep latency, total sleep time, amount of rapid eye
movement (REM) sleep, sleep eﬃciency, or arousals [43].
The only signiﬁcant ﬁnding in terms of sleep was shorter
duration of stage 1 of non-REM sleep in the subjects tak-
ing melatonin compared to the placebo group, but no
changes within the melatonin group before and after mela-
tonin [43]. Similarly, in a double-blind study of 1 or 5 mg
melatonin given at night, no eﬀect on sleep latency or
duration was found, recorded using EEG [48]. These
reports suggest that any sleep-promoting eﬀects of melato-
nin are short lived and eﬀects seem to be more pro-
nounced when melatonin is given during the day [49]. It is
also possible that subjects in some previous studies may
have had an expectation of the possible eﬀects of melato-
nin, which may have resulted in subjective reports of
somnolence. Two small studies of low-dose oral melatonin
administration in patients on the intensive care unit
reported minor eﬀects on sleep, but no eﬀect on sedation
requirements [50, 51].
We developed a whole blood model as a physiologically
relevant representation of early events in sepsis. Modeling
sepsis is not straightforward; animal models are fraught
with controversy [52], and although possible, modeling
sepsis in humans is unpleasant and at best can only actu-
ally model aspects of inﬂammation [53]. The interaction
between immune responses associated with sepsis is com-
plicated and diﬃcult to replicate in cell culture systems,
although whole blood models are potentially more physio-
logically relevant than single-cell-type models in terms of
reﬂecting complex immune cell–cell interactions. We found
that the respiratory burst of whole blood exposed to LPS/
PepG was decreased by both melatonin and 6-hydroxyme-
latonin, as reported previously in isolated neutrophils from
patients with pancreatitis [54]. Bacterial wall proteins such
as LPS and PepG promote inﬂammation via engagement
of toll-like receptors, leading to myD88-dependent inﬂam-
matory responses including the respiratory burst via
NADPH oxidase activity [55, 56] and resulting in activa-
tion of signaling pathways culminating in cytokine release.
Treatment of blood with melatonin or 6-hydroxymelato-
nin also resulted in dose-dependent suppression of LPS/
PepG-induced increases in IL-6 and lipid hydroperoxide
levels, while IL-10 was unaﬀected, conﬁrming previous
ﬁndings in models of sepsis [7, 14–16] and other disease
models [57]. The mechanism of the eﬀect of melatonin/6-
hydroymelatonin may be via antioxidant scavenging, but
melatonin has also been reported to aﬀect NADPH oxi-
dase activity [58] and several transcription factor pathways
involved in cytokine responses, possibly mediated through
eﬀects on mitogen-activated protein kinases (MAPK) [11,
57–59].
We also investigated the eﬀect of melatonin and 6-hy-
droxymelatonin on aspects of mitochondrial function in
isolated leukocytes exposed to LPS/PepG. Sepsis is associ-
ated with mitochondrial damage, which is thought to con-
tribute to the pathophysiology of organ dysfunction [3–6].
In the present study, we exposed leukocytes to sepsis-like
conditions for 18 hr to mimic the early stages of sepsis
and found increased intracellular total radical production
and intra-mitochondrial superoxide production, with con-
comitantly increased oxygen consumption, all of which
were attenuated by melatonin and 6-hydroxymelatonin at
all concentrations. We previously reported that melatonin
and other related indoles, including 6-hydroxymelatonin,
attenuated mitochondrial dysfunction induced by 7-day
exposure to LPS/PepG in human endothelial cells [11].
Similar protective eﬀects of melatonin on mitochondrial
function have been reported in models of sepsis in animals
[7, 30]. Mitochondrial membrane potential in leukocytes in
the present study increased upon LPS/PepG exposure and
was reduced to that seen in control cells by melatonin and
6-hydroxymelatonin. The increase in mitochondrial mem-
brane potential is required physiologically to enhance the
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bactericidal activity of phagocytes caused by the downre-
gulation of mitochondrial uncoupling protein-2 [60]. The
enhanced mitochondrial membrane potential is necessary
to drive increased production of mitochondrial ROS
(mROS) through boosting electron leak during oxidative
phosphorylation. Evidence indicates that mROS is an
important contributor to the bactericidal activity of the
respiratory burst and innate immune signaling by aug-
menting pro-inﬂammatory cytokine production via nuclear
factor jB (NFjB) and MAPK [61–64]. Treatment with
melatonin/6-hydroxymelatonin resulted in a return of
mitochondrial membrane potential to baseline, thus pre-
sumably contributing to the blunting of subsequent
inﬂammatory responses. Of course, this may have had an
unwanted eﬀect of reducing phagocytic cell killing of bac-
teria. However, in additional studies we found that the
ability of neutrophils to both phagocytose and kill
ingested E. coli was unaﬀected by melatonin or 6-hydroxy-
melatonin at concentrations up to 100 pg/mL.
Melatonin has been given previously to patients with
sepsis at relatively low doses, with the aim of inﬂuencing
sleeping patterns [50, 51], but we suggest that higher doses
of oral melatonin are likely to have beneﬁcial eﬀects on
inﬂammatory responses and are probably primarily medi-
ated via 6-hydroxymelatonin. A recently published study
of 100 mg melatonin given as an intravenous infusion over
an 8-hr period before injection of a very small dose of
LPS in a human model of endotoxemia showed only
minor eﬀects of melatonin on cytokine levels and lipid per-
oxidation products [65]. However, the changes seen in
response to LPS administration were small compared with
those seen both in other human models of endotoxemia
and in patients with sepsis [53]. Unfortunately, the levels
of melatonin or its metabolites were not reported, nor the
eﬀects on sleep or other side eﬀects, nor veriﬁcation of the
model in terms of inﬂammatory responses such as body
temperature, hormone levels, and leukocyte counts [65].
In summary, we showed that the levels of both melato-
nin and 6-hydroxymelatonin achieved after oral dosing of
melatonin were within the range of the doses at which anti-
oxidant and anti-inﬂammatory eﬀects were seen in blood
cultured under conditions mimicking sepsis and that there
were no side eﬀects. The variable responses between indi-
viduals should be considered when melatonin is adminis-
tered. We propose that administration of around 50 mg of
melatonin would generate melatonin and—perhaps more
importantly—6-hydroymelatonin levels that correspond to
concentrations at which attenuation of inﬂammatory and
oxidative stress biomarkers was seen ex vivo, even in those
subjects in whom melatonin levels were lowest.
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